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Abstract 
We have recently introduced a 1,4,7-triazacyclononane (TACN) based chelating system with 
additional five-membered azaheterocyclic substituents for complexation of radioactive Cu2+ ions. 
In this work, we investigated the complexation properties of these novel chelators with Ga3+. In 
labelling experiments, we could show that the penta- and hexadentate imidazole derivatives 
NODIA-Me 4 and NOTI-Me 1 can be labelled with 68Ga in specific activities up to ~30 MBq 
nmol-1, while the corresponding thiazole derivative NOTThia 2 did not label satisfactorily under 
identical conditions. NMR studies on the Ga complexes of 1 and the model compound NODIA-
Me-NH-Me 5 revealed formation of rigid 1:1 chelates with a slow macrocyclic interconversion 
and inert Ga-N bonds to the methylimidazole residues on the NMR time scale. The TACN-derived 
bifunctional chelator NODIA-Me was furthermore conjugated to a prostate-specific membrane 
antigen (PSMA) targeting moiety to give the corresponding bioconjugate NODIA-Me-PSMA 7. 
Serum stability and ligand challenge experiments of 68Ga-7 confirmed formation of a stable 
complex for up to 4h. The remaining coordination site of five-coordinate Ga complexes was found 
to be occupied by monodentate ligands including hydroxide and chloride anions depending on the 
conditions. According to density functional theory (DFT) calculations, coordination of 
monodentate ligands are energetically plausible. Finally, the labelled bioconjugate 68Ga-7 
exhibited rapid renal clearance in biodistribution studies performed by small animal PET imaging 
with no indication of transchelation/demetallation in vivo. Altogether, our results provide strong 
evidence for a stable Ga complexation of our novel TACN-based chelators bearing imidazole 
arms. Despite the formation of two complexes with different monodentate ligands in vitro, the 
imidazole type ligands show promise as chelating agents for the future development of gallium 
based radiopharmaceuticals. 
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Introduction 
In recent years, the positron-emitting radionuclide 68Ga has been used intensively in both 
preclinical and clinical research.1-11 Interest in 68Ga originates from its ready availability from 
commercial 68Ge/68Ga generator systems, which allow cost-effective, widespread use of 68Ga-
based radiopharmaceuticals at clinical centers that do not have access to local cyclotron facilities. 
The parent radionuclide 68Ge has a half-life of 271 days and typical commercial generators can be 
used for ≥1 year. Gallium-68 has a half-life of 67.7 min and decays primarily by positron emission 
(β+: 89%, Eβ+max = 1899 keV). Its half-life provides a close match with the pharmacokinetics of 
many peptides and other small molecules owing to a fast blood clearance as well as rapid diffusion 
and target localization. The availability of 68Ge/68Ga generator systems and optimal decay 
properties of 68Ga have spurred the development of 68Ga-based radiopharmaceuticals in recent 
years.12 The most prominent example for the clinical success of 68Ga-labelled 
radiopharmaceuticals is the family of 68Ga-labelled somatostatin analogs which include 
DOTATATE (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1),Tyr(3)-
octreotate) for PET imaging of neuroendocrine tumors.13-16 More recently, two urea-based 
radiopharmaceuticals 68Ga-HBED-CC-PSMA (also known as DKFZ-PSMA-11)17-24 and 68Ga-
PSMA Imaging & Therapy25-27 targeting the prostate specific membrane antigen (PSMA) have 
shown great promise in clinical PET imaging of prostate cancer and metastases.  
 Labelling biomolecules with radiometals for imaging and/or therapy generally requires the 
use of a bifunctional chelator (BFC). The BFC is designed to bind the radiometal at one terminus 
and contains at least one functional group as a second terminus for covalent linkage to a targeting 
vector of interest. Introduction of a BFC into a biomolecule can induce adverse effects on the 
radiolabelling chemistry, biological binding properties, and on the pharmacokinetics of the 
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radiotracer in vivo. The most commonly used BFC for 68Ga is the ligand DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) given in Scheme 1.28 Its popularity originated 
from its versatility in coordinating a wide range of medically important radiometals, e.g. 177Lu-
DOTATATE for somatostatin receptor radiotherapy. However, for DOTA conventional or 
microwave heating is required in order to obtain adequate radiochemical yields (RCYs) and 
specific activities.29-33 Another well-established family of BFCs for 68Ga is based on the 
macrocycle TACN (1,4,7-triazacyclononane) such as the ligands NOTA (1,4,7-triazacyclononane-
1,4,7-triacetic acid) and NODAGA (1,4,7-triazacyclononane-N-glutamic acid-N’,N’’-diacetic 
acid) shown in Scheme 1. These TACN based chelators have been radiolabelled efficiently at low 
temperatures and even at ambient temperature.34-37 Other ligands, reported more recently, that label 
under ambient conditions are the ligands TRAP (1,4,7-triazacyclononane-1,4,7-tris[methyl(2-
carboxyethyl)phosphinic acid)38-40 and PCTA (3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-
1(15),11,13-triene-3,6,9-triacetic acid).41-44 While most of the ligands used for 68Ga complexation 
are based on macrocycles, the acyclic ligand HBED-CC (N,N’-bis[2-hydroxy-5-
(carboxyethyl)benzyl]ethylenediamine-N,N’-diacetic acid) in Scheme 1 has recently received 
increased attention as the complexing unit of the radiopharmaceutical 68Ga-HBED-CC-PSMA.17-
24  
 We have recently introduced a novel chelating system based on the macrocycle TACN 
with pendant five-membered azaheterocycles, which was originally designed for stable 
complexation of radioactive Cu2+ ions.45 These ligands radiolabel efficiently with 64Cu under mild 
conditions over a wide pH range in high specific activities. The corresponding 64Cu complexes 
displayed high inertness/stability in vitro. While many ligands for Ga3+ complexation that utilize 
different O- and N-donor groups have been described, to the best of our knowledge, macrocyclic 
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ligands bearing azaheterocyclic pendant substituents with aromatic N-donors have not been 
reported. Interestingly, there are only a few reports in the literature on the Ga chemistry of five-
membered azaheterocycles in aqueous media.46-47 In the present work, we therefore sought to 
explore the potential of novel TACN derived chelators with azaheterocyclic residues for nat./68Ga3+ 
complexation.  
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Materials and Methods 
Chemicals and solvents of the highest grade commercially available were purchased from Sigma-
Aldrich (Schnelldorf, Germany) and TCI Europe (Zwijndrecht, Belgium), and used as received. 
1H and 13C NMR spectra were measured in MeOD or D2O at room temperature using a Bruker 
Avance III HD 500MHz NMR spectrometer (Rheinstetten, Germany). Chemical shifts are given 
in parts per million (ppm) and are reported relative to tetramethylsilane (TMS) or 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS), respectively. Coupling constants are reported in hertz (Hz). The 
multiplicity of the NMR signals is described as follows: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet. Low resolution electrospray ionisation mass spectrometry (LR-ESI(+)-MS) 
was performed on a PerkinElmer Flexar SQ 300 MS Detector (Rodgau, Germany). High resolution 
mass spectrometry (HR-ESI(+)-MS) was performed on a Thermo Scientific Exactive mass 
spectrometer (Langenselbold, Germany). Automated GMP conform radiolabelling with 68GaCl3 
was accomplished using a synthesis module (Pharmtracer, Eckert & Ziegler, Berlin, Germany) 
with an IGG100 generator (Eckert & Ziegler). High performance liquid chromatography (HPLC) 
was conducted on an Agilent (Waldbronn, Germany) 1260 Infinity System equipped with an 
Agilent 1200 DAD UV detector (UV detection at 220 nm) and a Raytest Ramona radiation detector 
(Straubenhardt, Germany) in series. A Phenomenex (Aschaffenburg, Germany) Jupiter Proteo 
(250 x 4.60 mm) column was used for analytical HPLC. The solvent system was A = H2O (0.1% 
TFA) and B = acetonitrile (0.1% TFA). The gradient was 0-1 min at 5% B, 1-12 min from 5% to 
50% B at a flow rate of 1 mL min-1. Semi-preparative HPLC was performed on a Knauer Smartline 
1000 HPLC system (Berlin, Germany) in combination with a Macherey Nagel VP 250/21 
Nucleosil 120-5 C18 column (Düren, Germany). Conditions A were 0-40 min from 5% to 60% B 
at a flow rate of 12 mL min-1. Conditions B were 0-10 min from 5% to 45% B, 10-13 min from 
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45% to 95% B at a flow rate of 12 mL min-1. Conditions C were 0-5 min from 5% to 10% B, 10-
20 min from 10% to 20% B at a flow rate of 12 mL min-1. Samples were lyophilized by using a 
Christ Alpha 1-2 LD plus lyophilizer (Osterode, Germany). All instruments measuring 
radioactivity were calibrated and maintained in accordance with previously reported routine 
quality-control procedures.48 Radioactivity measurements were made by using an Activimeter 
ISOMED 2010 (Nuklear-Medizintechnik, Dresden, Germany). For accurate quantification of 
radioactivity, experimental samples were counted for 1 min on a calibrated Perkin Elmer 
(Waltham, MA) 2480 Automatic Wizard Gamma Counter by using a dynamic energy window of 
400–600 keV for 68Ga (511 keV emission). Phosphorimaging was performed using a Cyclone Plus 
(Perkin Elmer). 
 
Synthesis 
The precursor Glu-CO-Lys(Ahx)-(tBu)3 ester was purchased from ABX (Radeberg, Germany). 
The ligand NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) was obtained from Chematech 
(Dijon, France). NOTI-Me 1 (1,4,7-tris((1-methyl-1H-imidazol-2-yl)methyl)-1,4,7-triazonane), 
NOTThia 2 (1,4,7-tris(thiazol-2-ylmethyl)-1,4,7-triazonane) and the disubstituted TACN 
derivative NODI-Me 3 (1,4-bis[(1-methyl-1H-imidazol-2-yl)methyl]-1,4,7-triazonane) were 
prepared as previously described.45  
 
NODIA-Me (2-(4,7-bis((1-methyl-1H-imidazol-2-yl)methyl)-1,4,7-triazonan-1-yl)acetic acid) (4) 
NODI-Me 3 (100 mg, 0.32 mmol) was mixed with glyoxylic acid monohydrate (58 mg, 0.63 
mmol) in 10 mL 1,2-dichloroethane followed by the addition of sodium triacetoxyborohydride 
(400 mg, 1.89 mmol). The suspension was allowed to stir for 16 h at room temperature. The 
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reaction mixture was concentrated to dryness by rotary evaporation and the residue redissolved in 
5 mL water (0.1% TFA) and further purified by semi-preparative RP-HPLC to give NODIA-Me 
4 as colorless solid after lyophilization (106 mg, 0.28 mmol, 90%). 1H NMR (MeOD): d = 2.77 
(m, 4H), 3.08 (m, 4H), 3.45 (m, 4H), 3.89 (s, 6H), 4.14 (s, 2H), 4.24 (s, 4H), 7.52 (d, J = 2.0, 2H), 
7.53 (d, J = 2.0, 2H) ppm; 13C NMR (MeOD): d = 35.3, 48.1, 49.6, 51.6, 54.2, 58.5, 120.3, 125.5, 
145.0, 170.1 ppm. HR-ESI(+)-MS calcd m/z for C18H29N7O2 (M+H)+: 376.2461, found: 376.2457. 
RP-HPLC (semi-preparative, conditions B): tR = 6.5 min; RP-HPLC (analytical, UV: 220 nm): tR 
= 3:11 min. 
 
NODIA-Me-NH-Me (2-(4,7-bis((1-methyl-1H-imidazol-2-yl)methyl)-1,4,7-triazonan-1-yl)-N-
methylacetamide) (5) 
NODIA-Me 4 (50 mg, 0.13 mmol) was reacted with methylamine hydrochloride (18 mg, 0.26 
mmol) in the presence of HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate) (101 mg, 0.26 mmol) and DIPEA (N,N-
diisopropylethylamine) (138 mg, 185 µL, 1.06 mmol) in 5 mL DMF for 4 h. The solvent was 
removed by azeotropic rotary evaporation using toluene (3 x 10 mL). The residue was redissolved 
in 5 mL of water:acetonitrile 0.1% TFA (50:50) and purified by semi-preparative RP-HPLC 
(conditions C). Fractions containing the product were combined followed by rotary evaporation of 
acetonitrile under vacuum. The remaining aqueous phase was then lyophilized to give NODIA-
Me-NH-Me 5 as colorless solid (44 mg, 0.11 mmol, 86%). 1H NMR (MeOD): d = 2.77 (m, 4H), 
2.86 (s, 3H), 3.07 (m, 4H), 3.42 (m, 4H), 3.91 (s, 6H), 4.18 (s, 2H), 4.23 (s, 4H), 7.56 (d, J = 2.0, 
2H), 7.57 (d, J = 2.0, 2H) ppm; 13C NMR (MeOD): d = 26.8, 35.4, 47.7, 49.4, 51.3, 54.0, 58.2, 
 Page 9 
 
120.3, 125.6, 145.0, 166.9 ppm. HR-ESI(+)-MS calcd m/z for C19H32N8O (M+H)+: 389.2772, 
found: 389.2769. RP-HPLC (semi-preparative, conditions C): tR = 13 min. 
 
natGa NOTI-Me (Ga-1) 
NOTI-Me 1 (20 mg, 0.05 mmol) and gallium nitrate hydrate (12 mg, 0.05 mmol) each dissolved 
in 500 µL water were combined and heated at 95 °C for 30 min. The natGa complex Ga-1 was 
obtained as colorless powder after lyophilization (32 mg, 0.05 mmol, 99%). 1H NMR (D2O, pD < 
2): d = 2.77 (m, 3H), 3.47 (m, 6H), 3.65 (m, 3H), 3.72 (s, 9H), 4.34 (d, J = 17.2, 3H), 4.81 (d, J = 
17.2, 3H), 6.48 (d, J = 1.8, 3H), 7.37 (d, J = 1.8, 3H); 13C NMR (D2O, pD < 2): d = 33.4, 53.5, 
55.3, 122.1, 127.2, 145.5 ppm. LR-ESI(+)-MS calcd m/z for C21H32GaN9 (M-H)2+: 239.5, found: 
239.5.  
 
natGa NODIA-Me-NH-Me (Ga-5) 
NODIA-Me-NH-Me 5 (20 mg, 0.05 mmol) and gallium nitrate hydrate (66 mg, 0.26 mmol) were 
each dissolved in 500 µL sodium acetate buffer (0.1 M, pH 4.0), combined and heated at 95 °C for 
30 min. After cooling to r.t., the natGa complex Ga-5 was purified by semi-preparative RP-HPLC 
to give the final product as colorless powder after lyophilization (110 mg, 0.24 mmol, 95%). 1H 
NMR (D2O, pD < 2): d = 2.96 (s, 3H), 3.03 (m, 2H), 3.15 (m, 2H), 3.27 (m, 2H), 3.57 (m, 6H), 
3.71 (s, 6H), 4.18 (s, 2H), 4.58 (d, J = 17.1, 2H), 4.68 (d, J = 16.8, 2H), 6.75 (s, 2H), 7.39 (d, J = 
1.7, 2H); 13C NMR (D2O, pD < 2): d = 28.0, 33.3, 53.2, 53.5, 53.9, 55.5, 59.5, 122.2, 127.2, 145.8, 
172.2 ppm. HR-ESI(+)-MS calcd m/z for C19H30N8O (M-2H)+: 455.1798, found: 455.1796. RP-
HPLC (semi-preparative, conditions B): tR = 9 min.  
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natGa(Cl) NODIA-Me-NH-Me (Ga(Cl)-5) 
For preparation of the chloro complex, Ga-5 (50 mg, 0.11 mmol) was incubated in 500 µL of a 1 
M sodium chloride solution (pH 5.0) at 95 °C for 30 min. After lyophilization, Ga(Cl)-5 was 
characterized by FT-IR and far-infrared IR (F-IR): n = 257, 288, 386, 427, 417, 514, 574, 613, 
660, 672, 704, 716, 795, 893, 919, 972, 1005, 1025, 1086, 1122, 1161, 1291, 1317, 1362, 1412, 
1471, 1512, 1569, 1683, 1734, 2962 cm-1.  
 
NODIA-Me-PSMA tert-butyl ester (Glu-CO-Lys(Ahx)-NODIA-Me-(tBu)3 ester) (6) 
NODIA-Me 4 (10.0 mg, 0.027 mmol), HATU (12.2 mg, 0.032 mmol) and DIPEA (6.9 mg, 93 µL, 
0.053 mmol) were dissolved in 200 µL DMF and the mixture was stirred for 30 min at room 
temperature. Then, Glu-CO-Lys(Ahx)-(tBu)3 ester (16 mg, 0.027 mmol) in 100 µL DMF was 
added and the reaction mixture was stirred for additional 4 h. The solvent was removed as 
described for 5 and the residue was dissolved in 3 mL of water:acetonitrile 0.1% TFA (50:50) and 
purified by semi-preparative RP-HPLC (conditions A). Fractions containing the product were 
combined followed by rotary evaporation of acetonitrile under vacuum. The remaining aqueous 
phase was then lyophilized to give NODIA-Me-PSMA tert-butyl ester ((15S,19S)-tri-tert-butyl 1-
(4,7-bis((1-methyl-1H-imidazol-2-yl)methyl)-1,4,7-triazonan-1-yl)-2,9,17-trioxo-3,10,16,18-
tetraazahenicosane-15,19,21-tricarboxylate) 6 as colorless solid (9 mg, 0.01 mmol, 36%). RP-
HPLC (semi-preparative, conditions A): tR = 35 min. LR-ESI(+)-MS calcd m/z for C48H84N11O9 
(M+H)+: 959, found: 958.8. 
 
NODIA-Me-PSMA (Glu-CO-Lys(Ahx)-NODIA-Me) (7) 
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NODIA-Me-PSMA tert-butyl ester 6 (9 mg, 0.01 mmol) was dissolved in 2 mL 5 M hydrochloric 
acid and the mixture allowed to stir for 16 h at room temperature. The reaction mixture was 
concentrated by rotary evaporation to a volume of 1 mL and further purified by semi-preparative 
RP-HPLC to give NODIA-Me-PSMA ((15S,19S)-1-(4,7-bis((1-methyl-1H-imidazol-2-
yl)methyl)-1,4,7-triazonan-1-yl)-2,9,17-trioxo-3,10,16,18-tetraazahenicosane-15,19,21-
tricarboxylic acid) 7 as colorless powder after lyophilization (7.2 mg, 9 µmol, 91%). HR-ESI(+)-
MS calcd m/z for C36H60N11O9 (M+H)+: 790.4576, found: 790.4564. RP-HPLC (semi-preparative, 
conditions B): tR = 14:50 min; RP-HPLC (analytical, UV: 220 nm): tR = 9:30 min. 
 
natGa NODIA-Me-PSMA (Ga(Cl)-7) 
NODIA-Me-PSMA 7 (500 µg, 0.63 µmol) in 250 µL water and 950 µL natGa stock (1 mM 
Ga(NO3)3 in 5 mM HCl) were mixed in 1.5 mL in sodium acetate buffer (0.1 M, pH 4.0) and the 
mixture was heated at 95 °C for 30 min. After cooling to r.t., the natGa complex Ga(Cl)-7 was 
purified using a C18 Sep-Pak cartridge (Waters), which was preconditioned using 5 mL of ethanol 
followed by 5 mL of water. After loading of the reaction mixture, the cartridge was washed with 
2 mL of water and the product was eluted off using 2 mL ethanol:water (50:50 v/v). HR-ESI(+)-
MS calcd m/z for C36H57GaN11O9 (M-2H)+: 856.3597, found: 856.3583. RP-HPLC (analytical, 
UV: 220 nm): tR = 9:39 min. 
 
 natGa NODIA-Me-PSMA (Ga(OH)-7) 
NODIA-Me-PSMA 7 (100 µg, 0.13 µmol) in 50 µL water and 20 µL natGa stock (10 mM Ga(NO3)3 
in 5 mM HNO3) were mixed in 200 µL in sodium acetate buffer (0.1 M, pH 4.5) and the mixture 
was heated at 95 °C for 15 min. After cooling to r.t., the natGa complex Ga(OH)-7 was purified 
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similarly to Ga(Cl)-7 using a C18 Sep-Pak cartridge (Waters). HR-ESI(+)-MS calcd m/z for 
C36H57GaN11O9 (M+H)+: 856.3597, found: 856.3585. RP-HPLC (analytical, UV: 220 nm): tR = 
9:20 min. 
 
Radiolabelling Experiments 
For the preparation of 68Ga complexes, stock solutions of the ligands NOTI-Me, NOTThia and 
NOTA were prepared in labelling buffer (sodium acetate 0.2 M pH 4.0). In a typical experiment, 
2.5 - 10 µL of chelator stock solution (corresponding to a final concentration of 0.5 µM – 10 µM) 
were mixed in the appropriate amount of labelling buffer followed by the addition of 50 µL (~5 – 
10 MBq 68GaCl3) generator eluate to give a final volume of 500 µL. After brief mixing, samples 
were either incubated at room temperature or 95 °C for 15 minutes. Analysis was initially 
performed by analytical RP-HPLC. The radiochemical conversion (RCC) was also checked by 
TLC using silica gel microfiber strips (Agilent, iTLC-SG glass microfiber) and DTPA solution (50 
mM, pH 7.4). Prior to the labelling experiments, additional tests were performed by TLC in which 
we used the 68Ga eluate without the presence of our ligands to exclude the formation of any 
colloidal gallium hydroxide. No differences between the HPLC and TLC analyzed samples were 
observed so that determination was continued by TLC. While 68Ga-NOTI-Me (68Ga-1) and 68Ga-
NOTThia (68Ga-2) remained at the origin (Rf = 0), uncomplexed 68Ga (in the form of the 
corresponding DTPA complex) moved with the solvent front (Rf = 1). Strips were then analyzed 
by phosphorimaging and RCC was calculated. Each experiment was performed at least in 
triplicate.  
 
68Ga NODIA-Me-PSMA (68Ga-7) 
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68Ga radiolabelling of the bioconjugate 7 was conducted by using the Modular-Lab PharmTracer 
automated synthesis module (Eckert&Ziegler, Berlin, Germany). Briefly, the 68Ge/68Ga-generator 
(Eckert&Ziegler, Model IGG100 Gallium-68 Generator) was eluted with 0.1 M HCl (7 mL) in 
accordance with the manufacturer’s protocol. The eluate (~600 MBq) was loaded onto a cation 
exchange column (Strata-XC [SCX], Phenomenex, Torrance, USA) and 68Ga was eluted from the 
SCX cartridge with 800 µL of a mixture of 0.13 M HCl in ~5 M NaCl(aq.) into the reaction vial. 
The reaction vial contained 20 µg NODIA-Me-PSMA 7 in a mixture of 400 µL sodium acetate 
buffer (pH 4.5) and 2 mL water. Labelling was accomplished by heating the reaction mixture at 
95 °C for 10 min. For purification, the solution was then loaded onto a C18 light cartridge (Waters, 
Milford, USA), which was washed with 3 mL saline and eluted with 1 mL 50 % ethanol. The final 
product was constituted by addition of 3 mL saline and sterilized by filtration using Millex 0.22 
µm filter (Millipore, Billerica, USA). RP-HPLC (analytical, radioactivity detector): tR = 9:40 min. 
The product 68Ga-7 was obtained in a decay corrected radiochemical yield (RCY) of ≥98% (n = 
10) and a radiochemical purity (RCP) of ≥98% with a specific activity of As = 31.2±1.2 MBq 
nmol-1. 
 
Lipophilicity (log D) measurements 
For log D measurements, 1–2 MBq of 68Ga-7 in saline (20 µL) was added to a mixture of phosphate 
buffered saline pH 7.4 (PBS) (480 µL) and octanol (500 µL) in 1.5 mL Eppendorf tubes. Samples 
were shaken for 1 h at room temperature. For separation, the samples were then centrifuged at 
13200 rpm for 5 min. From each phase, 100 µL were transferred into plastic tubes, and the 
radioactivity of the samples was counted using a Wizard Gamma Counter (Perkin Elmer). 
Experiments were performed in triplicate. 
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DTPA challenge measurements 
7–9 MBq (10 µL) of 68Ga-7 were added into 200 µL of 50 mM DTPA solution pH 7.4 
(diethylenetriamine penta-acetic acid) and the mixture was stored at room temperature. At selected 
time points, 20 µL samples were drawn and analyzed by analytical RP-HPLC. The percentage of 
intact 68Ga-7 conjugates was calculated from the HPLC chromatograms. Experiments were 
performed in triplicate. 
 
Serum stability and protein binding measurements 
For each experiment, 7–9 MBq (10 µL) of 68Ga-7 were added to human serum (1 mL, human male 
AB plasma, Sigma-Aldrich) in a 1.5 mL Eppendorf tube, which was pre-equilibrated at 37 °C in a 
cell incubator for 1 h. Samples were vortexed and stored at 37 °C in a cell incubator. At selected 
time points, 100 µL aliquots were taken from the serum solution and serum proteins removed by 
centrifugation using centrifuge tubes (Vivacon 500; 30 kDa molecular weight cut-off; Sartorius 
Stedium Biotech, Göttingen, Germany) at 4 G for 5 min at 4 °C. To the filter, 100 µL PBS were 
added followed by an additional centrifugation step. For determination of protein bound fraction, 
the filters and the filtrates were transferred into plastic tubes, and samples were counted using a 
Wizard Gamma Counter. A sample of the filtrate was kept on ice until HPLC analysis. The 
percentage of intact 68Ga-7 conjugates was calculated from the HPLC chromatograms. All 
experiments were performed in triplicate. 
 
Small animal PET Imaging 
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Small animal PET studies were carried out in accordance with the German Animal License 
Regulations and were approved by the animal care committee of the Regierungspräsidium 
Freiburg. Imaging was performed on a Focus 120 microPET scanner (Siemens Medical Solutions, 
USA). For PET imaging studies, nude mice (balb/c nude, Janvier Labs, Le Genest-Saint-Isle, 
France) (n = 3) were anesthetized with isoflurane (2-4% in air) and placed on the scanner. 
Immediately after scan start, animals were injected with 100 µL of 68Ga-7 (~3.7 MBq) in saline 
via a catheter into a the tail vein. Data were acquired for 60 min in list mode. Reconstruction was 
performed using unweighted OSEM2D. Image analysis was performed using AMIDE. Time-
activity curves (TACs) were constructed by manually drawing regions of interest (ROI) over the 
heart, the liver, the kidneys and the bladder. All ROIs were then copied on each of the frames, and 
time-activity curves of the ROI mean values were generated.  
 
Computational details 
All calculations were conducted by using DFT as implemented in either the Gaussian03W 
Revision B.04 or Gaussian09 Revision B.01 suite of ab initio quantum chemistry programs.49 
Normal self-consistent field (SCF) and geometry convergence criteria were employed throughout. 
Structures were optimized in the gas phase without the use of symmetry constraints. Harmonic 
frequency analysis based on calculated analytical second derivatives was used to characterize 
optimized structures as local minima. All calculations employed the B3LYP50-52 exchange-
correlation functionals with either the LANL2DZ53-56 or DGDZVP57-59 basis sets.  
 Solvation effects were incorporated60-61 iteratively via self-consistent reaction field (SCRF) 
calculations using the integral equation formalism polarisable continuum model (IEFPCM).62 Due 
to limitations in computational capacity, full geometry optimizations in the presence of the solvent 
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field were beyond our capacity. Therefore, optimized gas phase geometries were used as input 
structures for single point calculations incorporating the solvent reaction field. The influence of 
full geometry relaxation in the continuum solvent model is expected to be minor.63 The solute-
solvent boundary was defined by using a solvent excluding surface (SES).64 The molecular solute 
surface was defined by using the United Atom Topological model (UAHF) for the radii of the 
solute atoms.65 Water was used as a solvation model (dielectric constant, ε = 78.3553) which 
reflects the experimental medium used in the radiosynthesis and application of 68Ga-labelled PET 
radiotracers. Natural Bond Order (NBO) was performed using default parameters. Optimized 
structures and molecular orbitals were analyzed by using Chemcraft (version 1.7, build 382).  
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Results and Discussion 
In combination with additional donor groups, the preorganized geometry of the TACN ring, with 
its small ring size, appears to be optimal for complexation of small metal cations like Ga3+. On the 
other hand, the hard Lewis acid Ga3+ generally prefers hard, charge compensating oxygen donors 
such as carboxylates, phosphonates, phosphinates, etc.28, 66 However, there are also a few examples 
of ligands in the literature with rather soft donor atoms such as thiolates that form stable Ga 
complexes including TACN-TM (= 1,4,7-tris(2-mercaptoethyl)-1,4,7-triazacyclononane) and 6SS 
(= N,N’-bis(2,2-dimethyl-2-mercaptoethyl)ethylenediamine-N,N’-diacetic acid).67-69 We recently 
described the synthesis of a novel class of hexadentate ligands for tailored complexation of 
radioactive Cu2+ ions. These chelators are also based on the nine-membered TACN macrocycle 
and include up to three five-membered azaheterocycles such as imidazole and thiazole as 
additional donor groups.45 In particular, imidazole is considered to be a moderate s-donor and a 
weak p-acceptor, with electron donating properties that are intermediate between those of saturated 
amines such as ammonia and unsaturated amines such as pyridine.70 Moreover, thiazole is 
considered to be more aromatic than imidazole.71 In the spectrochemical series, both ligands are 
ranked above oxygen donors and below ammonia and pyridine and both ligands can be classified 
as borderline N donors.70, 72 We therefore sought to investigate the complexation properties of this 
novel class of ligands with nat/68Ga3+ and evaluate its potential for future use in radiopharmaceutical 
applications.   
   
Ligand and natGa Complex Syntheses  
Initial screening was performed on the trisubstituted derivatives NOTI-Me 1 and NOTThia 2 
(Scheme 2), which were prepared as previously described.45 Both ligands, however, lack a 
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functionality that allows covalent linkage to a targeting vector. A well-established method for 
covalent conjugation of a BFC to a targeting vector is the formation of a peptide bond between a 
carboxylic acid function of the BFC and an amino group of the biomolecule. Hence, we 
synthesized the BFC NODIA-Me 4 (Scheme 2), where we replaced one of the pendent 
azaheterocyclic arms of the original chelating system with an acetic acid residue to provide the 
possibility for the conjugation of biomolecules, while maintaining the complexation properties of 
this class of chelators. For the preparation of 4, the disubstituted compound 3 (NODI-Me) was 
used as starting material, which can be obtained during the synthesis of NOTI-Me 1.45 Reaction of 
3 with glyoxylic acid in the presence of the reducing agent sodium triacetoxyborohydride gave the 
BFC NODIA-Me 4 in 90% yield (Scheme 3).73 For more detailed studies on the complex formation 
with natGa3+, we also prepared the ligand NODIA-Me-NH-Me 5 (86%) as a model compound, in 
which the carboxylic acid was reacted with methylamine and HATU in order to mimic conjugation 
of a targeting vector by formation of an amide bond (Scheme 3). The corresponding Ga complex 
Ga-5 was also employed in the DFT calculations (vide infra). All ligands were fully characterized 
by 1D- and 2D NMR spectroscopy and mass spectrometry and their purity (>98%) was confirmed 
by analytical RP-HPLC. In order to assess the potential of this novel BFC in vivo, we conjugated 
NODIA-Me 4 using HATU to the commercially available precursor Glu-CO-Lys(Ahx)-(tBu)3 
(Scheme 3). After deprotection of the intermediate 6 in 5 M HCl and purification by semi-
preparative HPLC, the final PSMA-targeting bioconjugate 7 was obtained in 33% overall yield. 
The identity of compound 7 was confirmed by high resolution MS and its purity (>98%) was 
determined by analytical HPLC. For more detailed studies on the complex formation with Ga3+ 
and as reference compounds, complexes Ga-1, Ga-5 and Ga-7 were prepared by mixing equal 
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amounts of ligand and gallium nitrate stock solutions followed by heating at 95 °C for 30 min. All 
characterization data are given in the Supporting Information. 
 
68Ga Labelling Experiments  
For radiopharmaceutical applications, sufficient binding of the radiometal of interest is essential. 
In this respect, we initially determined the Ga complexation properties of the imidazole 1 and 
thiazole 2 derivative in comparison to the ligand NOTA in 68Ga labelling experiments (Figure 1). 
Labellings were performed manually at pH 4.0 in sodium acetate buffer to avoid the formation of 
insoluble gallium hydroxide. The investigated chelator concentration range of 0.5 µM – 10 µM 
corresponds to specific activities of As = ~2 – 40 MBq nmol-1. The ligand NOTI-Me 1 bearing 2-
methylimidazole substituents labelled readily with 68Ga in sufficient specific activities, even at 
ambient temperatures. Increasing the temperature to 95 °C resulted in a higher RCC and 
accordingly in higher specific activities. In contrast, the thiazole derivative NOTThia 2 did not 
label with 68Ga. Even at increased ligand concentrations and elevated temperatures no quantitative 
RRC could be achieved rendering thiazole type N donors unsuitable for Ga3+ complexation. The 
ligand NOTA, which is known to label under ambient temperatures74, on the other hand, gave 
quantitative RCCs at room temperature with specific activities of ~20 MBq nmol-1.  
 To demonstrate further the applicability of these novel chelators for envisaged 
radiopharmaceutical applications, we also performed 68Ga labelling of the PSMA-targeting 
bioconjugate 7 incorporating the BFC NODIA-Me 4 in a fully automated, GMP compliant process 
using the Eckert&Ziegler Pharmtracer module in combination with sterile single-use cassettes. 
Prior to the labelling reaction, the generator eluate (~600 MBq) was concentrated and purified by 
trapping on a cation exchange cartridge in accordance with previously reported methods.75 
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Labelling of the bioconjugate 7 was performed in sodium acetate buffer (pH 4.5) at 95 °C for 10 
min. After purification using a C18 Sep Pak cartridge, the product 68Ga-7 was obtained in a decay 
corrected radiochemical yield (RCY) of ≥98% (n = 10) and a radiochemical purity (RCP) of ≥98% 
with a specific activity of As = 31.2±1.2 MBq nmol-1. Labelling of our novel chelators requires 
slightly higher ligand concentrations or heating to achieve specific activities comparable to those 
obtained using NOTA. Nonetheless, the determined conditions for quantitative labelling and 
corresponding specific activities are more than sufficient for future radiopharmaceutical 
applications and the results of the labelling experiments clearly demonstrate the capability of these 
novel chelators to complex 68Ga, even under acidic conditions and ambient temperature.  
 
Structures of natGa complexes in solution 
In order to learn more about the metal binding properties of these novel chelates in solution, we 
performed a series of 1D- and 2D-NMR experiments on Ga-1 as well as on the model compound 
Ga-5. As expected, the 1H spectrum of the ligand NOTI-Me 1 at pD < 2 in Figure 2A shows only 
four resonances at 3.14 ppm (CH2 groups of TACN), 3.87 ppm (CH3 imidazole), 4.42 ppm (CH2 
bridging) and 7.47 ppm (imidazole protons). The corresponding 1H spectrum of Ga-1 in Figure 2B 
(pD < 2) significantly differs to that of the free ligand 1 consistent with the formation of a highly 
symmetric, hexadentate 1:1 chelate with a local C3 symmetry in solution. Upon Ga3+ coordination, 
the decrease of macrocycle flexibility results in a splitting of the CH2 resonances of the TACN 
macrocycle into a set of three multiplets in the range of ~2.7 – 3.7 ppm, which is consistent with 
an AA’MX coupling pattern, corresponding to a slow (ddd) Û (lll) ring conformational 
interconversion on the NMR time scale. In addition, the CH2 groups of the methylimidazole arms 
exhibit an AB coupling pattern consistent with their non-equivalence due to the long lifetime of 
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the corresponding Ga-N bonds on the NMR time scale. Interestingly, the imidazole protons shifted 
to higher field, in which the proton adjacent to the metal coordinated N donor is strongly shielded, 
which can be attributed to the ring current caused by the anisotropic effect of the aromatic 
imidazole rings. This contrasts with the Ga(NOTA) complex, in which the diasterotopic CH2 
groups of TACN gave symmetrical multiplets at 3.23 and 3.51 ppm, corresponding to a well 
resolved AA’MM’ multiplet pattern consistent with a fast conformational change of the TACN 
ring protons.76 Furthermore, the protons of the CH2 groups of the acetic acid residues gave a singlet 
at 3.88 ppm, consistent with a short Ga-O bond lifetime on the NMR time scale.76 The splitting 
pattern of Ga-1 is comparable to that of Ga(NOTP)3- (NOTP = 1,4,7-triazacyclononane-1,4,7-
tri(methylenephosphonate)) with inert Ga-O bonds and quite strong Ga-N bonds.77 In this respect, 
the presented NMR data for Ga-1 confirms formation of a rigid 1:1 complex with strong Ga-N 
TACN bonds and inert Ga-N bonds to the imidazole residues.  
 While compound 1 is a hexadentate ligand able to saturate the octahedral coordination sphere 
around the Ga3+ cation, the BFC NODIA-Me 4 provides only five donor atoms if the remaining 
acetic acid function is used for conjugation of biologically active molecules and, thus, leaving one 
coordination site of an octrahedral coordination unoccupied. During the HPLC characterization of 
68Ga-7, we observed the formation of another species in chloride free medium and at basic pH, 
which we attributed to an exchange of weakly coordinating, monodentate ligands such as chloride 
and hydroxide anions (vide infra). We therefore sought to investigate the coordination geometry 
of Ga-5 in more detail by NMR spectroscopic studies (Figure 2C and 2D). The proton NMR of the 
free ligand 5 in Figure 2C shows three broad multiplets for the TACN protons at 2.77, 3.07 and 
3.42 ppm. The singlet resonance at 2.86 ppm corresponds to the terminal CH3 group of the amide 
bond and the singlet at 3.91 ppm to the two CH3 groups of the imidazole residues. The CH2 signals 
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at 4.18 ppm and 4.23 ppm correspond to the CH2 groups of the acetate and methylimidazole arms, 
respectively. The protons of the imidazole resonate as doublets at 7.55 and 7.56 ppm. When 
coordinated to Ga3+ (pD < 2), the TACN resonances split into four multiplets for the equatorial 
and axial protons as seen in Figure 2D. This is representative for an ABMX coupling pattern, 
confirming a slow TACN ring conformational interconversion for Ga-5. Similar to Ga-1, the 
protons of the CH2 groups of the methylimidazole arms show an AB coupling pattern, consistent 
with an inert binding of the imidazole N donors to the metal center. The imidazole proton adjacent 
to the coordinated N donor is also strongly shielded as already seen for Ga-1. Interestingly, the 
CH2 protons of the carboxy function show a singlet at 4.18 ppm, which is not significantly shifted 
in comparison to the signal of the free ligand (4.18 vs. 4.23 ppm both in MeOD, see Supporting 
Information). This is consistent with no involvement of the amide function in metal binding 
because one would expect to see a shift of the corresponding resonance upon coordination to the 
metal center, even considering a short lifetime of the corresponding amide-N or carbonyl-O 
interaction. However, the presence of a singlet might also be attributed to the Cs symmetry of the 
Ga-5 complex. Nonetheless, from these results a fast exchanging coordination via the carbonyl-O 
or amide-NH in solution cannot entirely be excluded. In the proton NMR of Ga-5 in MeOD 
(Supporting Information), additional resonances for both imidazole protons and the methyl groups 
were obtained, while all other signals were not doubled. Obviously, two separate species are 
present in MeOD in the ratio of 5:1. The fact that only resonances of the methylimidazole residues 
are doubled indicates differences in close proximity to these protons. Since complex Ga-5 was 
prepared in the absence of chloride under acidic conditions, coordination of a water molecule or 
of the amide group might explain the presence of additional resonances. Altogether, the proton 
NMR of Ga-5 shows the formation of a 1:1 chelate with a slow conformational interconversion of 
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the macrocycle and inert Ga-N bonds for the imidazole donors. Even though the exact 
determination of the occupancy of the remaining coordination site was not possible by these 
experiments, it can be concluded that both ligands 1 and 5, in contrast to NOTA, form highly rigid 
complexes with Ga3+. It is also noteworthy that protonation of imidazole residues or even 
decomplexation at acidic pH (pD < 2) was not seen in the characterization of either Ga-1 or Ga-5. 
 
Stability Measurements 
Kinetic stability of the corresponding metal complex under biologically relevant conditions is 
essential for radiopharmaceuticals in order to avoid premature loss of the radiometal and/or 
transchelation in vivo. In addition to the NMR studies that revealed formation of rigid 1:1 chelates 
for ligands 1 and 5, we furthermore determined the stability of the conjugate 68Ga-7 in vitro by 
ligand challenge (DTPA) and serum stability studies (Figure 3). In saline and PBS, the product of 
the radiolabelling of 7 (assigned to 68Ga(Cl)-7; vide infra) was found to be stable for >4 h with 
respect to changes in RCP as determined by HPLC. These observations confirmed that no 
radiolysis or chemical degradation occurred during the course of the experiment (Figure 3A). 
Stability was further assessed by incubation in DTPA solution (50 mM, pH 7.4) at room 
temperature. No transchelation was noted for >4 h (Figure 3B), indicating that the 68Ga complex 
remained stable (~3% transchelation after 4 h, tR (68Ga-DTPA) = 2:4 min). However, at a pH > 7 
and in the absence of chloride anions, e.g. incubation in DTPA solution at pH 7.4 as for the ligand 
challenge experiment, formation of another species (tR = 9:20 min) (assigned to 68Ga(OH)-7; vide 
infra) that eluted just prior to the product peak (tR = 9:40 min) was noted. Over time, this newly 
formed species increased from ~1% at 15 min after synthesis to ~17% at 4 h (Figure 3B). A similar 
finding was observed in the serum stability study (pH > 7). After incubation in human serum at 37 
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°C for 1 h, the species giving rise to the new peak (tR = 9:20 min) was formed to ~20% and 
increased up to ~65% after 4 h (Figure 3C+D). Interestingly, apart from the formation of this new 
species, no significant degradation was observed (~1%) for up to 4 h. The protein associated 
fraction of 68Ga-labelled 7 was low at 14.6 ± 1.0% (n = 3). Overall, no activity associated with 
either a fully hydrolyzed [68Ga(OH)4]- or [68Ga(DTPA)]2- (both of which elute at the solvent front 
in the HPLC analysis) was observed in the stability measurements indicating that the gallium ion 
remained bound to the macrocyclic chelate under these conditions. Further, the close retention 
times between the initial 68Ga(Cl)-7 product and the new species suggested that the two species 
were extremely similar in size, shape and polarity. 
 
Studies on the Interconversion of 68Ga-7 
In general, Ga3+ cations in aqueous medium exhibit a preference for hexadentate coordination 
typically in an octahedral fashion.28 The ligand NODIA-Me 4 only provides five donor atoms for 
metal chelation and is consequently not capable of saturating the coordination sphere around the 
Ga3+ cation. As indicated, the fact that the retention time difference between the parent 68Ga(Cl)-
7 (9.40 min) and daughter (9.20 min) peaks was so close suggested that only a minor change in 
structure or polarity was occurring. Our hypothesis was that the remaining coordination site might 
be occupied by various monodentate ligands such as chloride, water, hydroxide ions, etc. or by the 
carbonyl oxygen atom of the adjacent peptide bond and that an interchange between two of such 
species occurs. Since the radiolabelling of 7 was performed in the presence of an excess of chloride 
ions (from the eluent used to wash off the 68Ga3+ activity after trapping on the strong cation 
exchange (SCX) cartridge), our assumption was that the remaining coordination site of 68Ga-
labelled 7 is occupied by a chloride ion at the end of radiolabelling after final purification and 
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formulation in saline. Furthermore, we found that under neutral or slightly acidic conditions (pH 
£ 7.0), e.g. as in the product formulation or PBS, no conversion of 68Ga-7 to the daughter species 
at 9.20 min occurred over a period of 4 h.  
 To probe the involvement of chloride ions as potential ligands, we performed further 
experiments. First, 68Ga-7 corresponding to the parent peak at 9.40 min was reacted with a solution 
of AgNO3(aq.). Sequestration of the chloride in solution led to quantitative conversion of the 
parent species (9.40 min) into the daughter product at 9.20 min (Figure S29). This reaction 
provided a strong indication that the formulated 68Ga complex contains a chloride anion, likely 
acting as a ligand and/or alternatively bound closely to the metal complex as a counter ion. Second, 
we prepared the corresponding non-radioactive Ga conjugates with and without chloride anions 
present in the reaction mixture and analyzed the products by RP-HPLC. The retention time in the 
UV chromatogram of the Ga complex with chloride anions present matched that observed for the 
radioactive 68Ga-labelled 7 species obtained at the end of the radiosynthesis. In contrast, the Ga 
complex prepared without chloride anions in the reaction conditions eluted with a shorter retention 
time (9.20 min) consistent with the formation of the new daughter species seen in the studies using 
radioactive gallium (Figures S30 and S31). All attempts to identify the coordination of either a 
chloride or a hydroxide ion bound to the natGa-5 complex using HRMS (high resolution mass 
spectrometry) were unsuccessful. Absence of a peak in HRMS is not confirmative and is 
potentially due to the labile coordinating character of both ions that may result in decomposition 
even under mild electrospray ionization conditions. Also, attempts to obtain single crystals of the 
model compound Ga-5 were not successful. Nonetheless, as indicated by DFT calculations (vide 
infra), if the two species (parent and daughter) are in equilibrium it should be possible to regenerate 
the parent peak (9.40 min) at pH < 7 in the presence of an excess chloride anions. Incubation of an 
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aliquot of a solution containing both the parent and daughter peak at pH 5.0 in the presence of 
excess sodium chloride resulted in formation of a single ‘parent’ peak. Representative HPLC 
chromatograms are given in Figure S32. The substitution reaction was also found to be pH 
dependent. Regeneration to the parent peak at 9.40 min could only be achieved below pH ≤ 7, 
which provides additional support that the daughter peak involves the formation of a 68Ga-
hydroxide complex. Furthermore, coordination of a chloride anion to Ga-5 could be confirmed by 
far infrared (F-IR) measurements. The corresponding F-IR spectrum of Ga-5 in the presence of 
chloride (Figure S33) shows an absorbance at ~387 cm-1, which is assigned to a Ga-Cl stretching 
vibration.47, 78 In a structurally similar Ga complex, the IR spectrum showed a Ga-Cl stretching 
vibration at 375 cm-1.79 This is also in accordance with the calculated IR spectra from our DFT 
calculations on different coordination modes of Ga-5 (Figure S35). The Ga-N stretching vibrations 
of the imidazoles at 210 and 258 cm-1 are in close agreement to vibrations of 227 and 248 cm-1 for 
a previously reported Ga imidazole complex.47 According to the IR measurements, the carbonyl 
group of the amide function does not bind to the metal in the solid state. The measured IR band of 
1683 cm-1 is comparable to the C=O stretching frequencies reported for acetamide and N,N-
dimethylformamide.80-82  
To investigate the potential ligand substitution reaction in more detail, we additionally 
performed a series of kinetic studies using different concentrations of initial 68Ga complex, varying 
pH, and different temperatures. Since the use of NaCl in the radiolabelling reaction was 
unavoidable, and attempts to remove chloride from the formulation using e.g. Ag Sep-Pak 
cartridges led to the exclusive formation of the daughter peak, it was not possible to control the 
chloride ion concentration in a systematic way. The presence of a relatively high concentration of 
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NaCl in the formulation meant that reactions were essentially conducted under pseudo-first order 
conditions with respect to chloride ion concentration.  
 Increasing the concentration of the 68Ga complex by a factor of 10 was found to increase the 
rate of daughter peak formation from an initial rate of 64 ± 2 pmol min-1 to 643 ± 27 pmol min-1 
(Figure 4A). This 10-fold increase in absolute conversion rate indicates that the reaction is first-
order with respect to the initial concentration of the parent 68Ga(Cl)-7complex. This conclusion 
was also supported by a plot of relative percentage of the daughter over parent peak (%) vs. time 
which showed that the relative rate of transformation of the peak at 9.40 min into the daughter 
peak at 9.20 min was identical irrespective of the initial 68Ga complex concentration (Figure 4B). 
In addition to confirming that the reaction is first order in 68Ga concentration, this experiment 
demonstrated that the same reaction process occurs in the concentration window studied (i.e. no 
other species were identified in the radio-HPLC chromatograms), and also that the reaction does 
not lead to the formation of an intermediate (observable) dimeric Ga complex in the rate 
determining step, i.e. the daughter peak is likely monomeric in 68Ga. 
 Next, the relative rate of reaction for conversion of the parent 68Ga complex into the daughter 
species was measured at different pH values in 0.1 M HEPES buffer (Figure 4C). The first 
observation was that in the control medium (water at pH 5.5) no reaction occurred. This was also 
consistent with the experimental observation that the parent 68Ga complex remains intact in the 
formulated product (saline; pH 5.5). However, at a pH > 7 and in the absence of chloride anions, 
the initial rate of conversion of parent into daughter species was found to increase when the pH of 
the buffer solution was increased in the range of 7.4 to 9.1. This observation supports the 
conclusions from the DFT calculations (vide infra) which predicted that the formation of a (Z)-
Ga(OH)-5 complex either via hydrolysis and reaction with (Z)-Ga-5 or by ligand substitution from 
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(Z)-Ga(Cl)-5 should be pH-dependent. Extrapolation of the data to estimate initial rates of reaction 
allowed the measurement of different values for log kobs, and a subsequent plot of these observed 
rates constants versus log[OH-] allowed the determination of the order of reaction with respect to 
hydroxide ion concentration (Figure 4D). Interestingly, the reaction was found to be non-linear in 
hydroxide concentration with a rate order, n = 0.62 ± 0.04. In non-ideal systems, non-integer rate 
orders in H+ or OH- ions are common and typically indicate that either the reaction mechanism is 
complex or that multiple, competing pathways may be plausible. 
 Overall, the experimental data provide strong support that the exchange reaction can be 
assigned to a chloride-to-hydroxide ligand substitution. The reaction is pH dependent, first order 
in gallium and non-linear in hydroxide concentration. Detailed kinetic studies are required to fully 
assign the mechanism. These experiments are ongoing but this work is beyond the scope of the 
current report. Collectively, the experimental data provide plausible, if not yet conclusive support 
for assignment of 68Ga(Cl)-7 as the parent species and 68Ga(OH)-7 as the daughter species. 
 
Computational Studies on the Complex Formation 
In addition to the experimental data, we also performed Density functional theory (DFT) 
calculations to probe the nature of the Ga-5 complex and the energetics of ligand substitution in 
more detail. Initial calculations investigated the energetic difference between the formation of a 
hexadentate complex with either E or Z isomerisation about the coordinated amide bond (Figure 
S36). DFT calculations predicted only a minor difference in free energy between the E and Z 
isomers. The Z isomer was calculated to be slightly more stable than the E isomer in both gas and 
solution phases independent of the used basis set. Subsequent calculations focused on the Z isomer. 
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 It is plausible that the amide donor ligand in Ga-5 could be labile giving either a penta-
coordinate Ga complex or a hexacoordinated complex in which the amide donor is replaced by a 
solvent molecule (H2O). Thus, we also investigated the possibility of solvent-induced structural 
isomerism (Figure S37). Unsurprisingly, dissociation of the Ga-amide coordination bond is 
energetically unfavorable with a calculated change in free energy of +109.4 kJ mol-1 (DGDZVP / 
water solvent model). Replacing the amide donor with a solvent molecule (H2O) partially 
compensated for this energetic difference but the reaction remained non-spontaneous with a 
change in free energy calculated between +17.7 to +93.4 kJ mol-1 (depending on the nature of the 
(H2O)n water cluster models used as energetic references). DFT calculations indicated that under 
pH neutral or acidic conditions, and in the absence of alternative donor ligands, the hexadentate 
(Z)-Ga-5 complex involving the coordination of an amide oxygen donor ligand is likely the 
predominant species in solution. 
 The reaction conditions employed to synthesize and purify the 68Ga-labelled NODIA-Me-
PSMA complexes 68Ga(Cl)-7 include an acidic (HCl), saturated sodium chloride solution, with 
preparation and final formulation of the product in saline (vide infra). It is plausible that the 
formulated 68Ga-complexes include chloride anions as counter ions and potentially as a 
coordinated donor ligand. Thus, DFT calculations were used to predict the possibility of forming 
an alternative, hexadentate (Z)-Ga(Cl)-5 complex in which the amide donor is replaced by a 
chloride ligand (Figure S38). The calculated free energy change, DG(sol) / kJ mol-1, in a water 
continuum solvent model for chloride ion addition to the (Z)-Ga-5 varied between -41.1 to +5.8 kJ 
mol-1 depending on the nature of the water cluster model. For the majority of the water cluster 
models, DFT calculations indicate that substitution of the amide donor ligand with a chloride 
ligand is thermodynamically spontaneous (DG(sol) < 0 kJ mol-1). This conclusion is consistent 
 Page 30 
 
with the electrostatic interaction between a 3+ charged Ga complex and a monoanionic chloride 
but also indicates that the Ga-Cl bond may be quite weak and labile.  
 Given the observed exclusive transformation of the parent species into a single daughter 
species under different conditions (AgNO3, DTPA at pH > 7.4 and serum), we hypothesized that 
a pH-dependent hydrolysis may occur affecting a ligand substitution reaction from the (Z)-Ga(Cl)-
5 to give a (Z)-Ga(OH)-5 complex. Calculated changes in free energy for the formation of the 
hydroxide complex from the (Z)-Ga-5 complex via ligand exchange on the (Z)-Ga(Cl)-5 complex 
are presented in Figure S39. In the case of chloride to hydroxide ligand exchange (Figure S40), 
two separate water cluster models were used for calculating the reference energies. Specifically, 
one water cluster (H2O)n, where n = 0 to 5, was used to calculate various solvated structures for 
the chloride ion upon release from the Ga complex. The second water cluster (n = 5) was required 
to provide a source of OH- anion with the by-product being the solvated Eigen ion H9O4+ which 
represents a commonly used approximation for a solvated proton. Again, the calculated change in 
free energy for Cl- to OH- ligand substitution was found to be dependent on the size of the water 
clusters used as an energy reference. Calculated DG(sol) values for the ligand substitution reaction 
varied from -9.7 to +37.1 kJ mol-1. This relatively small change in free energy suggests that, i) the 
species are likely to be in equilibrium, and ii) the reaction is likely pH dependent. Overall, the DFT 
calculations are consistent with the assignment of (Z)-68Ga(Cl)-7 as the parent species (peak at 
9.40 min) and (Z)-68Ga(OH)-7 as a daughter species (peak at 9.20 min). 
  
Biodistribution Studies by Small-animal PET imaging 
Finally, the stability of the radiolabelled bioconjugate 68Ga-7 was evaluated by small animal PET 
imaging in nude mice. Coronal MPIs (maximum intensity projections) of 68Ga-7 and 
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corresponding TACs (time activity curves) for organs of interest are given in Figures 5A and 5B, 
respectively. The bioconjugate 68Ga-7 exhibited fast blood clearance with an initial activity of 
~40% IA g-1 (injected activity per gram) at 1 min p.i. (post injection) decreasing to ~13% IA g-1 at 
10 min p.i. and essentially reaching background levels (~1.5% IA g-1) after 1 h. Transferrin is an 
endogenous serum protein with two Fe3+ binding sites acting as iron transporter. Transferrin binds 
Fe3+ with high affinity but also displays high affinity for Ga3+, which has a similar ionic radius to 
Fe3+. Due to the rapid blood clearance of the bioconjugate 68Ga-7, significant transchelation to 
transferrin does not occur confirming sufficient stability of the chelate in vivo. A similar uptake 
pattern was observed for the liver with ~25% IA g-1 at 1 min p.i. decreasing to ~9% IA g-1  at 10 
min p.i. and ~1.6% IA g-1 after 1 h, respectively. The formulated radiolabelled bioconjugate 7 
(assigned to 68Ga(Cl)-7) was found to be highly hydrophilic with a log D value of -5.04 ± 0.36. 
The high hydrophilicity of 68Ga-7 is reflected in its rapid renal excretion via the kidneys. At 1 min 
p.i., ~26% IA g-1 were already present in the kidneys peaking at 15 min p.i. with ~120% IA g-1 
followed by rapid excretion with ~4% IA g-1 at 1 h p.i.. In turn, the uptake in the bladder increased 
as the uptake in the kidneys decreases underlining the fast washout of 68Ga-7 from normal organs. 
Altogether, the biodistribution profile of 68Ga-7 matched that of an unretained but intact 
bioconjugate demonstrating high kinetic stability in vivo.  
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Conclusions 
From the trisubstituted ligands NOTI-Me 1 and NOTThia 2, only the imidazole derivative 1 labels 
with 68Ga, while the thiazole derivative 2 does not bind the radiometal under identical conditions 
rendering thiazole N donors unsuitable for Ga complexation. Achieved specific activities are 
comparable to those of existing chelators such as NOTA. Replacement of one imidazole arm by 
an acetic acid residue provided the bifunctional derivative NODIA-Me 4 with a functionality that 
allows covalent conjugation of a targeting vector. The hexadentate chelator 1 as well as the 
pentadentate model compound 5 revealed the formation of rigid 1:1 chelates with Ga3+ at acidic 
pH in solution with a slow macrocyclic interconversion and inert Ga-N bonds for the imidazoles 
confirming strong metal binding. The BFC 4 was furthermore coupled to a PSMA targeting moiety 
to give the bioconjugate 7. This was successfully labelled with 68Ga in a fully automated, GMP 
compliant process in high RCY and RCP with a specific activity of ~30 MBq nmol-1. Substitution 
of one imidazole arm by an acetic acid residue did not significantly alter the metal complex 
stability as demonstrated by serum stability and DPTA challenge experiments of the final 68Ga 
labelled PSMA targeting bioconjugate 7. More detailed investigations on these five-coordinate 
complexes revealed that the remaining/vacant coordination site of the octahedral Ga can be 
occupied by monodentate ligands such as chloride and hydroxide anions. Coordination of both 
monodentate ligands is concentration-dependent and these weakly associated ligands can undergo 
an exchange. Above pH 7 in the absence of chloride, coordination of hydroxide appears to be 
favored, whereas coordination of chloride occurs below pH 7 in the presence of chloride. This 
equilibrium is further supported by DFT calculations that revealed only small energetic differences 
for both complexes. In small animal PET imaging studies in healthy nude mice, the 68Ga labelled 
PSMA targeting conjugate NODIA-Me-PSMA 68Ga-7 is rapidly excreted from normal organs 
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consistent with sufficient stability in vivo. Despite the fact that gallium remains strongly 
complexed by the ligand NODIA-Me, the formation/interconversion of two different complexes 
in vitro might be considered to be a disadvantage due to their potentially different biological 
properties such as binding affinity and biodistribution. On the other hand, dramatic differences in 
biological behavior are not expected due to the close similarity of both complexes in size, charge 
and lipophilicity. Moreover, the five-coordinate ligand NODIA-Me might also be a promising 
candidate for the radiofluorination of a preformed Ga complex.79 More detailed in vivo studies of 
these chelators in combination with appropriate targeting vectors in tumor xenograft bearing mice 
will be reported. Investigations on the complex stability such as determination of formation 
constants are part of ongoing work. Notably, to the best of our knowledge, this is the first report 
of rigid and stable Ga imidazole complexes in aqueous media. Summarizing, TACN-based ligands 
bearing additional methylimidazole residues form stable complexes with 68Ga and corresponding 
bifunctional derivatives show promise as chelating agents for the future development of gallium 
based radiopharmaceuticals.  
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Figure and Scheme Legends 
 
Scheme 1. Common ligands for 68Ga chelation  
 
Scheme 2. Novel TACN derived chelators of this work bearing five-membered azaheterocyclic 
arms 
 
Scheme 3. Syntheses of the BFC NODIA-Me 4, model compound 5 and PSMA targeting 
conjugate 7. i) glyoxylic acid, NaBH(OAc)3, DCE; ii) methylamine, HATU, DIPEA, DMF; iii) 
Glu-CO-Lys(Ahx)-(tBu)3 ester, HATU, DIPEA, DMF; iv) 5M HCl, r.t. 
 
Figure 1. Radiochemical conversion of ligands NOTI-Me 1, NOTThia 2 and NOTA in 68Ga 
labelling experiments in 0.2 M sodium acetate pH 4.0 
 
Figure 2. Proton NMR spectra of (A) NOTI-Me 1, (B) Ga-1, (C) NODIA-Me-NH-Me 5 and Ga-
5 
 
Figure 3. Representative radio-HPLC chromatograms of 68Ga-7 showing formation of newly 
formed species after incubation in different media. (A) saline (product formulation) after 4 h, (B) 
50 mM DTPA pH 7.4 after 4 h, and human serum after 1 h and 4 h (C, D). 
 
Figure 4. (A) Plot of the absolute concentration (nM) of daughter peak 68Ga(OH)-7 (9.20 min.) 
vs. time for two different initial concentrations of the 68Ga complex. (B) Plot of the relative 
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percentage change (%) in the activity associated with the daughter peak 68Ga(OH)-7 with respect 
to that of the parent complex 68Ga(Cl)-7 vs. time. (C) Plot of the relative percentage change (%) 
in the activity associated with the daughter peak with respect to that of the parent complex vs. time 
at varying pH values (0.1M HEPES buffer) and in the control medium (water, pH 5.5). (D) Plot of 
the observed rate constants (log kobs) versus log[OH-] showing a linear relationship with a slope 
equal to the order of reaction with respect to the concentration of hydroxide anions. 
 
Figure 5. (A) Representative maximum intensity projection of the biodistribution of 68Ga-7 in 
healthy nude mice at different time points. (B) Corresponding time-activity curves for organs of 
interest 
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We recently demonstrated the applicability of 1,4,7-triazacyclononane derived ligands with up to 
three azaheterocyclic arms as chelating agents for 64Cu used in Positron Emission Tomography 
(PET). Here, we describe their complex formation with the PET isotope 68Ga3+. These ligands 
form rigid 1:1 chelates with natGa3+ in solution. In 68Ga3+ complexes of the five-coordinate 
bifunctional chelator NODIA-Me, the remaining coordination site of the octahedron is occupied 
by monodentate ligands such as chloride or hydroxide.   
 
 
